CCO of Pulse Biosciences (NASDAQ: PLSE) sells 60,000 shares

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised stock options and sold shares in mid-February. He exercised options covering 60,000 shares of Common Stock at a strike price of $1.53 per share and sold 60,000 shares in open-market transactions at weighted average prices of $23.37, $23.53, and $23.63 per share.

These trades were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025. Following the transactions, Danahy directly holds 43,298 shares of Common Stock and 305,000 stock options from a 2022 grant for up to 450,000 shares that vests over four years.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Danahy Kevin Patrick

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/12/2026		S(1)		20,000	D	$23.37(2)	43,298	D
Common Stock	02/13/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/13/2026		S(1)		20,000	D	$23.53(3)	43,298	D
Common Stock	02/17/2026		M(1)		20,000	A	$1.53	63,298	D
Common Stock	02/17/2026		S(1)		20,000	D	$23.63(4)	43,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.53	02/12/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	345,000	D
Stock Option (right to buy)	$1.53	02/13/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	325,000	D
Stock Option (right to buy)	$1.53	02/17/2026		M(1)			20,000	(5)	09/23/2032	Common Stock	20,000	$0	305,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

2. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.81 to $26.00 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

3. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $23.00 to $25.00 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

4. The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.98 to $24.99 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.

5. Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did PLSE’s Chief Commercial Officer report on this Form 4?

The Chief Commercial Officer exercised options for 60,000 Pulse Biosciences shares and sold 60,000 shares in open-market trades. These actions combined option exercises at $1.53 per share with subsequent sales at weighted average prices above $23 per share.

How many Pulse Biosciences (PLSE) shares did the CCO sell and at what prices?

The CCO sold 60,000 Pulse Biosciences common shares in three blocks of 20,000. Weighted average sale prices were $23.37, $23.53, and $23.63, with actual sale prices within stated ranges around those averages for each trading day.

Were the recent PLSE insider stock sales under a 10b5-1 trading plan?

Yes. The reported Pulse Biosciences sales were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025. Such plans pre-schedule trades, allowing insiders to sell shares according to predetermined instructions over time.

What stock options did the PLSE Chief Commercial Officer exercise?

The CCO exercised options to acquire 60,000 Pulse Biosciences common shares at a strike price of $1.53 per share. These options are part of a September 23, 2022 grant for up to 450,000 shares tied to his promotion and vesting over four years.

How many Pulse Biosciences shares and options does the CCO hold after these transactions?

After the reported trades, the CCO directly owns 43,298 Pulse Biosciences common shares. He also holds 305,000 stock options from the 2022 option grant, which originally covered up to 450,000 shares and vests in four equal annual installments.

What is the net share impact of the PLSE insider’s recent transactions?

Across the reported period, the CCO exercised options for 60,000 shares and sold 60,000 shares, resulting in net open-market sales of 60,000 shares. The option exercises increased his remaining option holdings while reducing directly held common shares.